# The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

> **NCT06496009** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 845 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** PD-1 Inhibitors

## Key facts

- **NCT ID:** NCT06496009
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2026-04-28
- **Final completion:** 2027-04-28
- **Target enrollment:** 845 (ESTIMATED)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06496009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06496009, "The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06496009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*